Last reviewed · How we verify
Carboplatin/Paraplatin
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death. Used for Ovarian cancer, Non-small cell lung cancer, Small cell lung cancer.
At a glance
| Generic name | Carboplatin/Paraplatin |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, disrupting DNA replication and transcription. This leads to apoptosis in rapidly dividing cancer cells. Unlike cisplatin, carboplatin has a different pharmacokinetic profile with potentially reduced nephrotoxicity and ototoxicity, though myelosuppression remains a significant toxicity.
Approved indications
- Ovarian cancer
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck cancer
- Breast cancer
- Testicular cancer
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Allergic reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin/Paraplatin CI brief — competitive landscape report
- Carboplatin/Paraplatin updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI